A retrospective study to describe clinical features and outcome in patients with immune checkpoint inhibitor (ICI)-associated myopathies
Latest Information Update: 20 May 2020
At a glance
- Drugs Avelumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 20 May 2020 New trial record
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology